Emergent Biosolutions
EBS
199 hedge funds and large institutions have $907M invested in Emergent Biosolutions in 2015 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 73 increasing their positions, 68 reducing their positions, and 11 closing their positions.
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
8% more funds holding
Funds holding: 184 → 199 (+15)
2.22% more ownership
Funds ownership: 81.84% → 84.06% (+2.2%)
7% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 68
1% more call options, than puts
Call options by funds: $658K | Put options by funds: $654K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $1.02B → $907M (-$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$14.4M |
| 2 |
ICRM
Insight Capital Research & Management
Walnut Creek,
California
|
+$6.8M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.78M |
| 4 |
Public Employees Retirement Association of Colorado
Denver,
Colorado
|
+$6.43M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$5.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$13.1M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.57M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$4.14M |
| 4 |
Goldman Sachs
New York
|
-$3.95M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$2.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
201
Trexquant Investment
Stamford,
Connecticut
| – | -$283K | -8,600 | Closed |
|
202
LPL Financial
San Diego,
California
| – | -$282K | -8,572 | Closed |
|
|
P
203
Pitcairn
Conshohocken,
Pennsylvania
| – | -$233K | -7,078 | Closed |
|
|
PA
204
Profund Advisors
Bethesda,
Maryland
| – | -$214K | -6,480 | Closed |
|
|
QI
205
Quotient Investors
New York
| – | -$211K | -6,400 | Closed |
|
206
SG Americas Securities
New York
| – | -$138K | -4,196 | Closed |
|
|
PCM
207
Prelude Capital Management
New York
| – | -$73K | -2,224 | Closed |
|
|
TFA
208
Transamerica Financial Advisors
St. Petersburg,
Florida
| – | -$4K | -100 | Closed |
|
|
MFS
209
MSI Financial Services
Springfield,
Massachusetts
| – | +$99 | +3 | New |
|
|
KCPG
210
Kavar Capital Partners Group
Leawood,
Kansas
| – | +$461 | +14 | New |
|
EBS Hedge Fund Activity: Q3 2015 in Review
199 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2015, worth a combined $907M — down 12% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new EBS positions and 11 closed out — a net gain of 16 holders — while 73 added to existing stakes and 68 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $14.4M. The largest seller was Bank of New York Mellon, cutting an estimated $13.1M.
- 199 institutional investors held Emergent Biosolutions (EBS) as of Q3 2015, up from 184 in Q2 2015.
- Funds reported $907M of Emergent Biosolutions stock for Q3 2015, down 12% quarter-over-quarter.
- 27 funds opened new Emergent Biosolutions positions in Q3 2015 and 11 closed out, a net change of +16 holders.
- The largest Emergent Biosolutions buyer in Q3 2015 was Manulife (Manufacturers Life Insurance), an estimated $14.4M added.
- The largest Emergent Biosolutions seller in Q3 2015 was Bank of New York Mellon, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2015.